title: Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
authors.affiliation: Developmental Therapeutics and Genitourinary Cancer Programs, University of Southern California Norris Comprehensive Cancer Center, Los Angeles.
authors.forename: A
authors.initials: A
authors.lastname: Goldkorn
authors.affiliation: Department of Genitourinary Oncology, M. D. Anderson Cancer Center, Houston, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Aparicio
authors.affiliation: Developmental Therapeutics and Genitourinary Cancer Programs, University of Southern California Norris Comprehensive Cancer Center, Los Angeles;. Electronic address: diquinn@med.usc.edu.
authors.forename: D I
authors.initials: DI
authors.lastname: Quinn
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D001859:Bone Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000494:pharmacology*
chemical_list: D000736:Androstenes; D000737:Androstenols; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D043823:Taxoids; D000077143:Docetaxel; D010669:Phenylthiohydantoin; C540278:enzalutamide; C089740:abiraterone